Medtronic Recall Raises Red Flag For DCBs Below The Knee
Executive Summary
Drug-coated balloons have emerged as one of the next major product segments within interventional cardiology, particularly for the treatment of peripheral arterial disease, but they appear to have hit their first major bump in the road. In November, Medtronic notified clinicians that it was recalling and discontinuing sales of its In.Pact Amphirion DCB for below-the-knee revascularization in patients with critical limb ischemia, based on forthcoming data from the company’s IN.PACT DEEP clinical study.
You may also be interested in...
Study Links Paclitaxel To Lower-Leg Amputations
New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.
Vascular Interventional Devices: New Avenues For Growth
Manufacturers are finding it harder to innovate in the vascular interventional devices as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in renal denervation, drug-coated balloons, and renal artery stenting; still there are some promising areas, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.
Re-Evaluating Growth Opportunities In Vascular Interventional Device Markets
Manufacturers are finding it harder to innovate in the vascular interventional device arena as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in the areas of renal denervation, drug-coated balloons, and renal artery stenting; still there are areas of opportunity that continue to look promising, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.